Products

LY2801653 1206799-15-6

1.Inquiries will be replied within 24 hours
2.We could supply various packages as you required
3.To protect the profit of our agents, price will not show on website, please send inquiries to get the price.
4.Fast delivery, goods arrive your office within 3 to 5 days
5.Please click "Inquiry" or "Email" below to get the price
 
Synonyms
Appearance
white powder
Chemical Formula
C30H22F2N6O3
Solubility
Molecular Weight
552.53
Storage and Stability
in stock
CAS No.
1206799-15-6
Purity
99.5%
Introduction
LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM. IC50 & Target: Ki: 2 nM (c-Met) In Vitro: LY2801653 demonstrates effects on MET pathway-dependent cell scattering and cell proliferation. The mean IC50 value (n=6 determinations) of LY2801653 for inhibition of MET auto-phosphorylation in HGF-stimulated H460 cells is 35.2±6.9 nM and the IC50 for MET auto-phosphorylation in S114 cells is 59.2 nM. Transfection with the MET variants confers growth-factor independence and treatment with LY2801653 inhibits growth of these MET variant clones with an IC50 ranging from 3-fold more potent (V1092I) to approximately 6-fold less potent (L1195V) compare with the growth inhibition of cells with the MET wild-type sequence. LY2801653 (2, 5, and 10 μM) reduces the number of viable TFK-1 and SZ-1 cells in a dose and time dependent manner, and significant inhibits wound healing for TFK-1 and SZ-1 cell lines. LY2801653 inhibits cell invasion in TFK-1 and SZ-1 cells in a concentration dependent mannerIn Vivo: LY2801653 demonstrates anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects. LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a pharmacodynamic residence time (Koff) of 0.00132 min-1 and t1/2 of 525 min. LY2801653 treatment inhibits MET phosphorylation with a composite TED50 (50 % target inhibition dose) of 1.2 mg/kg and a composite TED90 (90 % target inhibition dose) of 7.4 mg/kg. LY2801653 (20 mg/kg) reduces TFK-1 tumor growth significantly relative to vehicle control. LY2801653 inhibits the growth of intra- and extrahepatic CCC xenograft tumors.

Thank you for your company product support!

CAS No. :

Product Name :

Number :

Your name:
*

Phone:

Email:
*

The company or laboratory name:
*